New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
08:04 EDTNKTRNektar announces dosing of first subject in Phase 1 study for NKTR-171
Nektar Therapeutics announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
08:24 EDTNKTREnzon says Nektar granted motion to dismiss breach of contract complaint
Subscribe for More Information
February 1, 2016
09:02 EDTNKTRNektar announces publication of findings for NKTR-214
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use